SI0914118T1 - Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators - Google Patents

Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Info

Publication number
SI0914118T1
SI0914118T1 SI9730462T SI9730462T SI0914118T1 SI 0914118 T1 SI0914118 T1 SI 0914118T1 SI 9730462 T SI9730462 T SI 9730462T SI 9730462 T SI9730462 T SI 9730462T SI 0914118 T1 SI0914118 T1 SI 0914118T1
Authority
SI
Slovenia
Prior art keywords
triazoles
diphenyl
substituted
metal chelators
pharmaceutical metal
Prior art date
Application number
SI9730462T
Other languages
English (en)
Slovenian (sl)
Inventor
Rene Lattmann
Pierre Acklin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0914118(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI0914118T1 publication Critical patent/SI0914118T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9730462T 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators SI0914118T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25
PCT/EP1997/003315 WO1997049395A1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
EP97928269A EP0914118B1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Publications (1)

Publication Number Publication Date
SI0914118T1 true SI0914118T1 (en) 2003-04-30

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730462T SI0914118T1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Country Status (37)

Country Link
US (3) US6465504B1 (zh)
EP (1) EP0914118B1 (zh)
JP (1) JP3541042B2 (zh)
KR (1) KR100616378B1 (zh)
CN (1) CN1146415C (zh)
AP (1) AP1127A (zh)
AR (1) AR007479A1 (zh)
AT (1) ATE226435T1 (zh)
AU (1) AU718037B2 (zh)
BG (1) BG64248B1 (zh)
BR (1) BR9709973A (zh)
CA (1) CA2255951C (zh)
CY (2) CY2429B1 (zh)
CZ (1) CZ291470B6 (zh)
DE (3) DE122007000020I2 (zh)
DK (1) DK0914118T3 (zh)
ES (1) ES2187785T3 (zh)
FR (1) FR06C0049I2 (zh)
GE (1) GEP20084355B (zh)
HK (1) HK1020530A1 (zh)
HU (1) HU226232B1 (zh)
IL (1) IL127212A0 (zh)
LT (1) LTC0914118I2 (zh)
LU (1) LU91291I2 (zh)
MY (1) MY129541A (zh)
NL (1) NL300248I2 (zh)
NO (3) NO317180B1 (zh)
NZ (1) NZ333308A (zh)
OA (1) OA10946A (zh)
PL (1) PL194758B1 (zh)
PT (1) PT914118E (zh)
RU (1) RU2208010C2 (zh)
SI (1) SI0914118T1 (zh)
SK (1) SK284319B6 (zh)
TR (1) TR199802693T2 (zh)
TW (1) TW533205B (zh)
WO (1) WO1997049395A1 (zh)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
AU2004298761A1 (en) * 2003-12-19 2005-06-30 Novartis Ag Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
US20080114001A1 (en) * 2005-01-28 2008-05-15 Manley Paul W Use of Pyrimidylaminobenzamides for the Treatment of Diseases that Respond to Modulation of Tie-2 Kinase Activity
MX2007009591A (es) * 2005-02-10 2007-09-12 Novartis Ag Metodos para disposicion mejorada de farmacos.
KR20080003933A (ko) * 2005-05-31 2008-01-08 노파르티스 아게 철이 발병에 관여하는 간질환의 치료
EP1940360A1 (en) * 2005-10-19 2008-07-09 Novartis AG Dispersible tablets comprising deferasirox
WO2007051773A1 (en) * 2005-11-01 2007-05-10 Novartis Ag Method of scintigraphy
NZ572299A (en) * 2006-05-09 2010-07-30 Novartis Ag Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
NZ572155A (en) 2006-05-23 2011-11-25 Novartis Ag Use of deferasirox for treating iron overload resulting from hereditary haemochromatosis
CL2007002026A1 (es) 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
EP2049108A1 (en) * 2006-08-04 2009-04-22 Novartis AG Treatment of endocrine dysfunction using iron chelators
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
MX2009005619A (es) 2006-11-29 2009-06-08 Novartis Ag Formas poliformicas del deferasirox (icl670a).
US20080262060A1 (en) * 2007-01-29 2008-10-23 Toth Zoltan G Crystalline forms of Deferasirox
AU2008250041A1 (en) * 2007-05-14 2008-11-20 Novartis Ag Use of iron chelator for the treatment of myocardial infarction
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
EP2062572A1 (en) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
CZ301873B6 (cs) 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
US20110171138A1 (en) * 2008-06-02 2011-07-14 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
CN102639557A (zh) 2009-03-19 2012-08-15 美国加州大学洛杉矶海滨分校医学中心的洛杉矶生物医学研究所 用于治疗毛霉菌病和其它真菌性疾病的疫苗组合物和方法
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
CN102638985A (zh) 2009-12-07 2012-08-15 Mapi医药公司 地拉罗司的制备方法和地拉罗司多晶型物
CA2805568A1 (en) 2010-07-08 2012-01-12 Ratiopharm Gmbh Oral dosage form of deferasirox
US8907083B2 (en) * 2010-08-25 2014-12-09 Ramamohan Rao Davuluri Process for the preparation, of 2-(2-hydroxyphenyl)-benz [1, 3] oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-IH-I, 2, 4-triazolTI-yl] benzoic acid
AP3578A (en) * 2010-10-01 2016-02-08 Cipla Ltd Pharmaceutical composition comprising deferasirox
US9018389B2 (en) 2010-11-24 2015-04-28 Alembic Pharmaceuticals, Ltd. Process for the preparation of Deferasirox
JP5900968B2 (ja) 2011-01-14 2016-04-06 株式会社ダステック 高分子鉄キレート剤
US20140276107A1 (en) 2011-10-14 2014-09-18 Photocure Asa Photodynamic diagnosis
WO2013053904A1 (en) 2011-10-14 2013-04-18 Photocure Asa Stent
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
ES2650118T3 (es) * 2013-03-06 2018-01-17 Biocon Limited Proceso para la preparación de deferasirox
CU24348B1 (es) * 2013-03-08 2018-05-08 Novartis Ag Formulaciones orales de deferasirox
MX2015015553A (es) * 2013-05-10 2016-06-17 Cipla Ltd Composicion farmceutica de dosis baja.
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
PT2946771T (pt) 2014-05-20 2019-06-27 Sanovel Ilac Sanayi Ve Ticaret As Formulação de comprimido dispersível em água compreendendo deferasirox
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
EP3268035A4 (en) 2015-03-10 2018-10-31 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
PE20181496A1 (es) 2015-10-23 2018-09-18 Vifor Int Ag Inhibidores de ferroportina novedosos
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
EP4052698A1 (en) 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH84663A4 (zh) 1963-01-24 1964-11-14
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
KR20050098029A (ko) 2005-10-10
DE122007000020I1 (de) 2007-05-24
ATE226435T1 (de) 2002-11-15
JP2000507601A (ja) 2000-06-20
WO1997049395A1 (en) 1997-12-31
DE69716602D1 (de) 2002-11-28
NO2018014I1 (no) 2018-04-17
CY2007005I2 (el) 2018-12-12
AP1127A (en) 2002-12-06
CZ427298A3 (cs) 1999-03-17
RU2208010C2 (ru) 2003-07-10
IL127212A0 (en) 1999-09-22
NZ333308A (en) 2000-05-26
NL300248I1 (nl) 2007-02-01
CY2429B1 (en) 2004-11-12
PT914118E (pt) 2003-02-28
CZ291470B6 (cs) 2003-03-12
MY129541A (en) 2007-04-30
FR06C0049I1 (zh) 2007-03-09
US6723742B2 (en) 2004-04-20
NO2018014I2 (no) 2018-11-19
NO986024L (no) 1998-12-21
DE122007000020I2 (de) 2010-12-30
DK0914118T3 (da) 2003-02-24
CA2255951A1 (en) 1997-12-31
NO2006017I1 (no) 2006-12-18
US6465504B1 (en) 2002-10-15
HK1020530A1 (en) 2000-05-12
BG64248B1 (bg) 2004-07-30
US6596750B2 (en) 2003-07-22
PL330119A1 (en) 1999-04-26
EP0914118B1 (en) 2002-10-23
HUP9903111A3 (en) 2000-06-28
FR06C0049I2 (fr) 2007-04-27
CN1223579A (zh) 1999-07-21
ES2187785T3 (es) 2003-06-16
NO2006017I2 (no) 2011-07-04
TW533205B (en) 2003-05-21
NO317180B1 (no) 2004-09-06
KR100616378B1 (ko) 2006-08-28
HU226232B1 (en) 2008-07-28
OA10946A (en) 2003-02-27
SK178598A3 (en) 1999-06-11
LU91291I9 (zh) 2018-12-27
BG103003A (en) 1999-09-30
GEP20084355B (zh) 2008-04-29
HUP9903111A2 (hu) 2000-01-28
JP3541042B2 (ja) 2004-07-07
CN1146415C (zh) 2004-04-21
NO986024D0 (no) 1998-12-21
LTC0914118I2 (lt) 2018-12-27
PL194758B1 (pl) 2007-07-31
AU718037B2 (en) 2000-04-06
TR199802693T2 (xx) 1999-05-21
DE69716602T2 (de) 2003-06-26
CY2007005I1 (el) 2010-07-28
NL300248I2 (nl) 2007-03-01
LTPA2007001I1 (lt) 2018-06-25
US20030069273A1 (en) 2003-04-10
AP9801407A0 (en) 1998-12-31
AU3262997A (en) 1998-01-14
BR9709973A (pt) 1999-08-10
LU91291I2 (fr) 2007-01-29
US20030203954A1 (en) 2003-10-30
AR007479A1 (es) 1999-10-27
EP0914118A1 (en) 1999-05-12
SK284319B6 (sk) 2005-01-03
CA2255951C (en) 2006-10-10

Similar Documents

Publication Publication Date Title
HK1020530A1 (en) Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
GB2319250B (en) Derivatives of 6,8-Difluoro-7-Hydroxycoumarin
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
GB9518115D0 (en) Triazole derivatives and their use as therapeutic agents
NZ329176A (en) 2,5-dioxo-imidazolidine derivatives and medicaments
PL329484A1 (en) Triazolyl merkaptides and their apllication as microbicides
HUP0003332A3 (en) Triazole compounds and the use thereof as dopamine-d3-ligands
EP0788489A4 (en) HETEROCYCLIC COMPOUNDS AND THEIR USE
GB2290538B (en) Metal organic compounds and their use
HUP9600730A1 (en) 1,4-tetrazolinone-derivatives and use thereof as herbicides
GB9422682D0 (en) Herbicidal methods, compositions and compounds
HK1023124A1 (en) Oxime derivatives and their use as fungicides
GB9426290D0 (en) Composition,compound and use
HK1044772A1 (zh) 雜環n-丙酮基苯甲酰胺以及它們作為殺菌劑的使用
SG81238A1 (en) Use of triphenylmethyl-1,2,3-triazoles
GB9426293D0 (en) Composition,compound and use
HUP9601395A2 (en) Composition containing amino-triazole and 1,2,4-triazin-5-on derivative and use thereof
PL301984A1 (en) Derivatives of 3-phenyl-5-methylisoxzaole and 4,5-dihydroisoxasole
SI0888356T1 (en) Condensed 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
GB9510729D0 (en) Compound, composition and use
GB9620738D0 (en) Sordarin and derivatives thereof for use as crop antifungal agents
PL303026A1 (en) Novel heterocyclic sulphonamidic compounds and pharmaceutical agent
HU9403034D0 (en) Fungicidal compositions and process for their use
ZA972790B (en) Heterocyclic compounds and their preparation and use.